Latest studies
- RecruitingPHASE3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This study looks at a new drug, Surovatamig, combined with rituximab, for people with previously untreated follicular lymphoma. It compares this new combination therapy with standard treatments to see if it works better and is safe.
Untreated Follicular LymphomaHong Kong - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersHong Kong - RecruitingPHASE3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
This study is testing a new medicine, mezagitamab, for adults with a bleeding condition called ITP. We want to see if it helps keep platelet counts stable. It's given by injection under the skin.
Immune Thrombocytopenic Purpura (ITP)Hong Kong - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisHong Kong - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsHong Kong - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesHong Kong - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseHong Kong - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaHong Kong - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
Non-small Cell Lung CancerHong Kong - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerHong Kong - Active not recruitingPHASE3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments, Iberdomide and Lenalidomide, after a stem cell transplant for multiple myeloma. It aims to find out which one works better at keeping the cancer under control following initial treatment.
Multiple MyelomaHong Kong - RecruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
Prostate CancerProstatic NeoplasmsHong Kong - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisHong Kong - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerHong Kong - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesityHong Kong - RecruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosisBRAF Gene MutationHong Kong - RecruitingPHASE2
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
This study looks at a new combination treatment for advanced bowel cancer that has spread. It combines a new drug, VVD-133214, with an existing immunotherapy, pembrolizumab. The aim is to see if this combination works better than pembrolizumab alone for certain types of bowel cancer.
Colorectal AdenocarcinomaHong Kong - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesHong Kong - RecruitingPHASE3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
This study looks at a new medicine called mezagitamab for a kidney problem called IgA nephropathy. It compares mezagitamab to a dummy medicine to see if it lowers protein in the urine and helps protect kidneys. All adults over 18 with this condition can take part.
Kidney DiseaseHong Kong - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerHong Kong - RecruitingPHASE3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is testing a new medicine, nucresiran, for people with a heart condition called transthyretin amyloidosis cardiomyopathy. Doctors want to see if it can improve health, reduce heart-related problems, and make patients feel better compared to a dummy medicine.
Transthyretin Amyloidosis With CardiomyopathyHong Kong - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, divarasib, for advanced lung cancer with a specific genetic change (KRAS G12C). It compares divarasib to existing treatments, sotorasib or adagrasib, to see how well they work and if they are safe.
Non-Small Cell Lung CancerKRAS G12C Lung CancerHong Kong - Active not recruitingPHASE3
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
This study looks at a new combination treatment for teenagers and adults with moderate to severe eczema. It combines a new tablet called upadacitinib with steroid creams to see how well it works and if it's safe.
Atopic DermatitisHong Kong - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
This study looks at new drug combinations for advanced lung cancer (non-small cell lung carcinoma) that has specific genetic changes (EGFR mutation) and has stopped responding to a previous treatment called osimertinib. It compares these new drug combinations with standard chemotherapy.
Carcinoma, Non-Small-Cell LungHong Kong - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
Carcinoma, Non-Small-Cell LungHong Kong - Enrolling by invitationPHASE2, PHASE3
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
This study looks at the long-term safety and effects of a medicine called sibeprenlimab for people with a kidney condition called IgA Nephropathy. It's for those who have already been part of earlier studies with this medicine.
Immunoglobulin A NephropathyHong Kong - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.
Hepatocellular CarcinomaHong Kong - RecruitingPHASE1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
This study looks at a new treatment called AZD5492 for lupus, myositis, and rheumatoid arthritis. It checks how safe it is, how well the body handles it, and how it works in adults.
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesRheumatoid ArthritisHong Kong - RecruitingPHASE3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
This study looks at a new drug, palazestrant, combined with standard treatment (ribociclib) for advanced breast cancer that is ER-positive and HER2-negative. It compares this new combination to the standard treatment alone to see if it works better and is safe for people who haven't had other treatments for their advanced cancer.
Breast CancerLocally Advanced Breast CancerMetastatic Breast CancerER Positive Breast CancerHong Kong - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
Non Small Cell Lung Cancer NSCLCHong Kong - Active not recruitingPHASE3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
This study looks at a new drug, DB-1303/BNT323, for advanced breast cancer that's 'HER2-low' and hormone-positive. It compares the new drug to standard chemotherapy to see if it can stop the cancer from growing for longer.
Metastatic Breast CancerHong Kong - Active not recruitingPHASE3
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study looks at a new medicine, sacituzumab tirumotecan, for advanced stomach or oesophagus cancer. It compares this new medicine to standard treatments to see if it's safer and works better for patients who have already had other treatments.
Gastroesophageal CancerHong Kong - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerHong Kong - RecruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
Non-small Cell Lung CancerHong Kong - Active not recruitingPHASE3
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
This study is looking into the long-term safety and effectiveness of a new medication called Enlicitide Decanoate. It's for adults with high cholesterol who have already taken part in previous studies of this drug. The aim is to see how well it works and if it's safe over a longer period.
HypercholesterolemiaHong Kong - RecruitingPHASE3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
This study is looking into a new medicine called Seladelpar for people with a liver condition called Primary Biliary Cholangitis (PBC) and mild liver scarring (cirrhosis). It aims to see how well Seladelpar works compared to a dummy pill to improve health outcomes.
Primary Biliary CholangitisHong Kong - RecruitingPHASE2, PHASE3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This study is testing a new medicine, CSL300, for adults with advanced kidney disease on dialysis. It aims to see if CSL300 can improve heart health and is safe, especially for those with existing heart conditions or diabetes.
End Stage Kidney DiseaseHong Kong - RecruitingPHASE3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This study looks into new ways to treat advanced stomach and gut cancers called GIST. It compares a new drug called CGT9486 (bezuclastinib) combined with an existing drug, sunitinib, against sunitinib alone, to see which works better for patients who haven't responded well to other treatments.
Advanced Gastrointestinal Stromal TumorsMetastatic CancerHong Kong - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
Breast CancerHong Kong - Active not recruitingPHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This study looks at a new drug, bomedemstat, for essential thrombocythemia (ET). It compares bomedemstat to standard treatments for people whose current medicine, hydroxyurea, isn't working well or causes too many side effects. We want to see if bomedemstat is safer and works better.
Essential ThrombocythemiaHong Kong - RecruitingPHASE3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in people who are newly diagnosed. It's comparing a new drug, bleximenib, with existing treatments (Venetoclax and Azacitidine) and a dummy drug (placebo) to see how well they work.
Leukemia, Myeloid, AcuteHong Kong - RecruitingPHASE3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.
Metabolic Dysfunction-Associated Steatotic Liver DiseaseHong Kong - Active not recruitingPHASE3
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
This study is testing a new gene therapy called delandistrogene moxeparvovec for boys with Duchenne Muscular Dystrophy (DMD). It aims to see if it's safe and effective for those who can and cannot walk. Some boys will receive the treatment, others a dummy treatment.
Duchenne Muscular DystrophyHong Kong - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Hong Kong - Active not recruitingPHASE3
Atrasentan in Patients With IgA Nephropathy
This study is testing a new medicine, atrasentan, for people with a kidney disease called IgA nephropathy. It compares atrasentan to a dummy pill (placebo) to see if it can slow down kidney damage and improve kidney function.
IgA NephropathyImmunoglobulin A NephropathyHong Kong - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer MetastaticHong Kong - Active not recruitingPHASE3
Nipocalimab in Moderate to Severe Sjogren's Disease
This study is testing a new drug called nipocalimab for people with moderate to severe Sjögren's disease. Researchers want to see if it's safe and effective compared to a dummy treatment (placebo) alongside their usual care.
Sjogrens SyndromeHong Kong - Active not recruitingPHASE2
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
This study is checking if the benefits of bepirovirsen for Hepatitis B last over time. It's for people who previously took part in a bepirovirsen trial and showed good results. No new treatment is given in this follow-up study, just monitoring.
Hepatitis BHong Kong - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Hong Kong - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerHong Kong